Dr. Joyce is Chief of the Structural Biology group within the Emerging Infectious Diseases Branch. His group utilizes structural biology with a focus on structure-based vaccine design, small molecule inhibitors, and viral antigen-antibody structures. The structural biology group utilizes X-ray crystallography and electron microscopy to study and understand immune responses and vaccine-host-virus interactions e.g. antibody-antigen interaction. Most recently, the group has focused on the design and development of a protective SARS-CoV-2 vaccine, and understanding protective immune responses against SARS-CoV-2 following infection or vaccination.
Dr. Joyce received a B.Sc. (Hons) in Biochemistry from the National University of Ireland, Galway in 2001, followed by a Ph.D. in Structural Biology from the University of Leicester in 2006. He then began work on the structural characterization of human immunoreceptors with Dr. Peter Sun in the Laboratory of Immunogenetics at NIH. In 2011, he moved to the NIH’s Vaccine Research Center working with Dr. Gary Nabel, Dr. Peter Kwong and Dr. John Mascola on the structure-based design of HIV-1, Influenza and RSV vaccine candidates. In 2016, Dr. Joyce joined the Henry M. Jackson Foundation and established the structural biology group at WRAIR.
Dr. Joyce is an author of over 80 peer-reviewed scientific manuscripts, and a co-inventor on 7 awarded patents and over 50 patent pending applications on vaccine immunogens and monoclonal antibody therapeutics for coronaviruses, flaviviruses, HIV-1, Influenza, RSV, and hMPV. He has been recognized within the Top 1% of Global Highly Cited researchers by Clarivate Analytics since 2018.
Selected Publications
Dearlove B, Lewitus E, Bai H, Li Y, Reeves DB, Joyce MG, Scott PT, Amare MF, Vasan S, Michael NL, Modjarrad K, Rolland M. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci U S A. 2020 Aug 31;. doi: 10.1073/pnas.2008281117. [Epub ahead of print] PubMed PMID: 32868447.
Joyce MG, Wheatley AK, Modjarrad K. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks. Cell. 2020 Jul 9;182(1):7-9. doi: 10.1016/j.cell.2020.06.017. PubMed PMID: 32649880; PubMed Central PMCID: PMC7346785.
Joyce MG, Sankhala RS, Chen WH, Choe M, Bai H, Hajduczki A, Yan L, Sterling SL, Peterson CE, Green EC, Smith C, de Val N, Amare M, Scott P, Laing ED, Broder CC, Rolland M, Michael NL, Modjarrad K. A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein. bioRxiv. 2020 Mar 17;. doi: 10.1101/2020.03.15.992883. PubMed PMID: 32511298; PubMed Central PMCID: PMC7217142.
Dussupt V, Sankhala RS, Gromowski GD, Donofrio G, De La Barrera RA, Larocca RA, Zaky W, Mendez-Rivera L, Choe M, Davidson E, McCracken MK, Brien JD, Abbink P, Bai H, Bryan AL, Bias CH, Berry IM, Botero N, Cook T, Doria-Rose NA, Escuer AGI, Frimpong JA, Geretz A, Hernandez M, Hollidge BS, Jian N, Kabra K, Leggat DJ, Liu J, Pinto AK, Rutvisuttinunt W, Setliff I, Tran U, Townsley S, Doranz BJ, Rolland M, McDermott AB, Georgiev IS, Thomas R, Robb ML, Eckels KH, Barranco E, Koren M, Smith DR, Jarman RG, George SL, Stephenson KE, Barouch DH, Modjarrad K, Michael NL, Joyce MG, Krebs SJ. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020 Feb;26(2):228-235. doi: 10.1038/s41591-019-0746-2. Epub 2020 Feb 3. PubMed PMID: 32015557; PubMed Central PMCID: PMC7018608.
Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019 Mar;20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019 Feb 11. PubMed PMID: 30742080; PubMed Central PMCID: PMC6380945.
Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018 May 15;92(10). doi: 10.1128/JVI.02002-17. Print 2018 May 15. PubMed PMID: 29514901; PubMed Central PMCID: PMC5923077.
Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, Yang ES, Tsybovsky Y, Wheatley AK, Crank MC, Boyington JC, Prabhakaran MS, Narpala SR, Chen X, Bailer RT, Chen G, Coates E, Kwong PD, Koup RA, Mascola JR, Graham BS, Ledgerwood JE, McDermott AB. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol. 2017 Jul 14;2(13). doi: 10.1126/sciimmunol.aan2676. PubMed PMID: 28783708.
Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet EJ, Tsybovsky Y, Yang Y, Georgiev IS, Guttman M, Lees CR, Pancera M, Sastry M, Soto C, Stewart-Jones GBE, Thomas PV, Van Galen JG, Baxa U, Lee KK, Mascola JR, Graham BS, Kwong PD. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 2016 Sep;23(9):811-820. doi: 10.1038/nsmb.3267. Epub 2016 Aug 1. PubMed PMID: 27478931; PubMed Central PMCID: PMC5016229.
Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, Zhang B, Zhang Y, Asokan M, Boyington JC, Bylund T, Darko S, Lees CR, Ransier A, Shen CH, Wang L, Whittle JR, Wu X, Yassine HM, Santos C, Matsuoka Y, Tsybovsky Y, Baxa U, Mullikin JC, Subbarao K, Douek DC, Graham BS, Koup RA, Ledgerwood JE, Roederer M, Shapiro L, Kwong PD, Mascola JR, McDermott AB. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 2016 Jul 28;166(3):609-623. doi: 10.1016/j.cell.2016.06.043. Epub 2016 Jul 21. PubMed PMID: 27453470; PubMed Central PMCID: PMC4978566.
Wang L, Shi W, M. Gordon Joyce, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman MC, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao S, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nature Comm. 2015. 6:7712. PMID: 26218507.
All publications